

POSTER PRESENTATION

Open Access

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints

Nicolas L Losa^{1*}, Michael Cruise², Ada Tam¹, Elizabeth Wick¹, Elizabeth Hechenbleikner¹, Janis M Taube¹, Richard Blosser³, Hongni Fan⁴, Hao Wang⁴, Brandon Lubber⁴, Ming Zhang⁴, Nickolas Papadopoulos⁴, Kenneth Kinzler⁴, Bert Vogelstein⁴, Cynthia Sears⁴, Robert A Anders¹, Drew Pardoll¹, Franck Housseau⁴, Nicholas Siegel⁴

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

We examined the immune microenvironment of primary colorectal cancer (CRC) using immunohistochemistry, laser capture microdissection/qRT-PCR, flow cytometry and functional analysis of tumor infiltrating lymphocytes. A subset of CRC displayed high infiltration with activated CD8+ CTL as well as activated Th1 cells characterized by IFN-gamma production and the Th1 transcription factor Tbet. Parallel analysis of tumor genotypes revealed that virtually all of the tumors with this active Th1/CTL microenvironment had defects in mismatch repair, as evidenced by microsatellite instability (MSI). Counterbalancing this active Th1/CTL microenvironment, MSI tumors selectively demonstrated highly up-regulated expression of multiple immune checkpoints, including five - PD-1, PD-L1, CTLA-4, LAG-3 and IDO - currently being targeted clinically with inhibitors. These findings link tumor genotype with the immune microenvironment, and explain why MSI tumors are not naturally eliminated despite a hostile Th1/CTL microenvironment. They further suggest that blockade of specific checkpoints may be selectively efficacious in the MSI subset of CRC. Our findings are the first to demonstrate a link between a genetically defined subtype of cancer and its corresponding expression of immune checkpoints in the tumor microenvironment. The mismatch repair defective subset of CRC selectively up-regulates at least 5 checkpoint molecules that are targets of inhibitors currently being clinically tested. Furthermore, our results were clinically validated in a

Phase II study at Hopkins which showed mismatch-repair status as a predictor of clinical benefit to immune checkpoint blockade with pembrolizumab.

Authors' details

¹Johns Hopkins University School of Medicine, Baltimore, MD, USA.

²Cleveland Clinic, Cleveland, OH, USA. ³Johns Hopkins University: School of Medicine, Baltimore, MD, USA. ⁴Johns Hopkins Hospital, Baltimore, MD, USA.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P410

Cite this article as: Losa et al.: The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. *Journal for Immunotherapy of Cancer* 2015 **3**(Suppl 2):P410.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



¹Johns Hopkins University School of Medicine, Baltimore, MD, USA
Full list of author information is available at the end of the article